118 completed, 16 unknown, 15 terminated, 13 not yet recruiting. 181 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 181 | Completed 118, Unknown 16, Terminated 15, Not yet recruiting 13, Recruiting 8, Active not recruiting 6, Withdrawn 5 |
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis | Phase 4 | Not yet recruiting | Boston Children's Hospital | 100 | 2031-01-01 | 2026-03-10 |
| Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 50 | 2026-12-01 | 2026-09-04 |
| Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in Dermatophytosis Itraconazole, Luliconazole Cream 1%, Bifonazole cream 1% - Tinea Corporis, Tinea Cruris | Phase 4 | Not yet recruiting | University of Faisalabad | 182 | 2026-12-01 | 2026-11-12 |
| AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis | Phase 4 | Not yet recruiting | Forefront Dermatology S.C | 250 | 2026-11-11 | 2026-10-02 |
| A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis Dupilumab - Atopic Dermatitis | Phase 4 | Not yet recruiting | Sanofi | 56 | 2026-10-28 | 2026-10-29 |
| Abrocitinib Dose Tapering in Patients With Atopic Dermatitis Abrocitinib - Atopic Dermatitis | Phase 4 | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2026-10-01 | 2026-09-29 |
| Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series Patch 1 (Expired), Patch 2 (non-expired) - Allergic Contact Dermatitis | Phase 4 | Not yet recruiting | University of Calgary | 100 | 2026-09-01 | 2026-08-14 |
| The Impact of Dietary Salt on the Severity of Eczema Sodium chloride tablets, Placebo Tablets - Eczema, Atopic Dermatitis | Phase 4 | Recruiting | University of California, San Francisco | 40 | 2026-08-10 | 2026-09-10 |
| Azithromycin in Atopic Dermatitis Betamethasone or tacrolimus ointments, Azithromycin - Atopic Dermatitis | Phase 4 | Not yet recruiting | Cairo University | 40 | 2026-08-01 | 2026-07-20 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. Roflumilast Cream 0.15% - ITCH, Atopic Dermatitis | Phase 4 | Recruiting | Integrative Skin Science and Research | 40 | 2026-07-21 | 2026-08-13 |
| The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease Sodium chloride tablets, Placebo Tablets - Atopic Dermatitis (Eczema), Psoriasis | Phase 4 | Recruiting | University of California, San Francisco | 50 | 2026-07-14 | 2026-09-09 |
| Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema Placebo Cream, Crisaborole 2% Cream - Atopic Dermatitis (AD), Atopic Eczema | Phase 4 | Not yet recruiting | Jinnah Postgraduate Medical Centre | 270 | 2026-03-01 | 2026-03-06 |
| Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis Crisaborole 2% Topical Application Ointment [EUCRISA, tacrolimus 0.1% - Atopic Dermatitis | Phase 4 | Not yet recruiting | Hayat Abad Medical Complex, Peshawar | 148 | 2026-03-01 | 2026-03-02 |
| Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis Application of crisaborole twice daily, Tacrolimus ointment in atopic dermatitis - Dermatitis, Atopic, Eczema | Phase 4 | Not yet recruiting | Cairo University | 30 | 2026-02-01 | 2026-01-26 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| Effect of 0.75% Piroctone Olamine Shampoo on the Hair and Scalp Microbiota of Hijab-Wearing Women With Seborrheic Dermatitis in Indonesia Piroctone Olamine 0.75% Shampoo, Ketoconazole Shampoo, 2% - Seborrheic Dermatitis | Phase 4 | Completed | Universitas Indonesia | 86 | 2026-01-12 | 2026-09-03 |
| Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab dupilumab - Severe Atopic Dermatitis (AD) | Phase 4 | Withdrawn | Regeneron Pharmaceuticals | 2025-11-11 | 2025-11-28 | |
| Topical Terbinafine Versus Hydrocortisone Combined With Oral Itraconazole for Seborrheic Dermatitis Itraconazole, Terbinafine 1% cream, Hydrocortisone 1% cream - Seborrheic Dermatitis | Phase 4 | Completed | Can Tho University of Medicine and Pharmacy | 76 | 2025-07-07 | 2026-10-30 |
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis lebrikizumab - Atopic Dermatitis | Phase 4 | Active not recruiting | Johann E Gudjonsson MD PhD | 48 | 2025-07-02 | 2026-09-15 |
Showing 20 of 181. Sign in to see all of them.
Dermatitis, Atopic (136) · Eczema (29) · Dermatitis, Seborrheic (7) · Diaper Rash (7) · Pruritus (7) · Psoriasis (7) · Dermatitis, Allergic Contact (5) · Asthma (4) · Tinea Cruris (4) · Dermatitis, Contact (3) · Stevens-Johnson Syndrome (3) · Tinea Pedis (3) · Bronchiolitis Obliterans Syndrome (2) · Facies (2)
Skin and Connective Tissue Diseases (181) · Skin Diseases (180) · Skin Diseases, Eczematous (165) · Immune System Diseases (148) · Hypersensitivity (144) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (137) · Genetic Diseases, Inborn (137) · Hypersensitivity, Immediate (137) · Skin Diseases, Genetic (136) · Pathological Conditions, Signs and Symptoms (17) · Skin Diseases, Papulosquamous (15) · Signs and Symptoms (11) · Skin Manifestations (11) · Dermatitis, Contact (10)
dupilumab (27) · pimecrolimus (21) · Tacrolimus (15) · crisaborole (11) · Adrenal Cortex Hormones (5) · Cyclosporine (5) · Hydrocortisone (4) · Petrolatum (4) · Sodium Chloride (4) · abrocitinib (4) · lebrikizumab (4) · Omalizumab (3) · Triamcinolone Acetonide (3) · montelukast (3) · retapamulin (3)
Novartis (10) · Sanofi (8) · University of California, San Francisco (8) · Astellas Pharma Inc (7) · Stiefel, a GSK Company (4) · Wake Forest University Health Sciences (4) · Cairo University (3) · Derm Research, PLLC (3) · Innovaderm Research Inc. (3) · Murdoch Childrens Research Institute (3) · Novartis Pharmaceuticals (3) · Technische Universität Dresden (3) · Wake Forest University (3) · Allerderm (2) · Bayer (2)
United States (90) · Germany (12) · Canada (9) · Switzerland (8) · United Kingdom (8) · China (7) · Australia (6) · Brazil (6) · Spain (6) · Egypt (4) · France (4) · Netherlands (4) · Belgium (3) · Denmark (3) · Dominican Republic (3)
Katrina Abuabara, MD (3) · Robert Bissonnette, MD (3) · Alan Fleischer, MD (2) · Amy Paller, MD (2) · Anya Loncaric (2) · Fu-Tong Liu, M.D., Ph.D. (2) · Leon H. Kircik, M.D. (2)
PMID 16680006, PMID 18385500, PMID 19127072, PMID 19403473, PMID 19863501, PMID 20070141, PMID 21039407, PMID 21099191, PMID 21121981, PMID 21533301, PMID 22134563, PMID 22404192, PMID 22805051, PMID 22920495, PMID 22951056, PMID 23374261, PMID 23377341, PMID 23388687, PMID 23545917, PMID 23675632, PMID 24435467, PMID 24731086, PMID 24846590, PMID 25231568, PMID 26179009, PMID 26598458, PMID 28330497, PMID 28491950, PMID 31764962, PMID 32212104, PMID 32947457, PMID 33760691, PMID 33969657, PMID 36806068, PMID 36824052, PMID 37181420, PMID 37429687, PMID 37799965, PMID 37946302, PMID 40274377, PMID 40973558, PMID 41350756, PMID 41611123, PMID 42027418, PMID 42126851, PMID 42617697
2018 (3), 2004 (1), 2008 (1), 2009 (1), 2023 (1), R21AR082620 (1), U19AI117673 (1)